156 related articles for article (PubMed ID: 37222093)
21. Vemurafenib (BRAF Inhibitor) Therapy for Orbital Erdheim-Chester Disease.
Gupta A; Yeganeh A; Rootman D; Goldberg R
Ophthalmic Plast Reconstr Surg; 2017; 33(6):e138-e139. PubMed ID: 28099231
[TBL] [Abstract][Full Text] [Related]
22. Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA.
Evseev D; Kalinina I; Raykina E; Osipova D; Abashidze Z; Ignatova A; Mitrofanova A; Maschan A; Novichkova G; Maschan M
Int J Hematol; 2021 Dec; 114(6):725-734. PubMed ID: 34383272
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults.
Cao XX; Sun J; Li J; Zhong DR; Niu N; Duan MH; Liang ZY; Zhou DB
Ann Hematol; 2016 Apr; 95(5):745-50. PubMed ID: 26858028
[TBL] [Abstract][Full Text] [Related]
24. Inhibitor of BRAF
Smirnova SY; Al-Radi LS; Moiseeva TN; Gemdzhian EG; Yakutik IA; Julhakyan HL; Novikov VA; Galstyan GM; Sudarikov AB
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):427-430. PubMed ID: 33811006
[TBL] [Abstract][Full Text] [Related]
25. BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity.
Pettirossi V; Santi A; Imperi E; Russo G; Pucciarini A; Bigerna B; Schiavoni G; Fortini E; Spanhol-Rosseto A; Sportoletti P; Mannucci R; Martelli MP; Klein-Hitpass L; Falini B; Tiacci E
Blood; 2015 Feb; 125(8):1207-16. PubMed ID: 25480661
[TBL] [Abstract][Full Text] [Related]
26. Dramatic Efficacy of Interferon and Vemurafenib on Psychiatric Symptoms Revealing
Razanamahery J; Abdallahoui M; Chabridon G; Fromont A; Tarris G; Idbaih A; Comby PO; Godard F; Haroche J; Audia S; Bonnotte B
Front Immunol; 2022; 13():918613. PubMed ID: 35874752
[TBL] [Abstract][Full Text] [Related]
27. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses.
Haroche J; Charlotte F; Arnaud L; von Deimling A; Hélias-Rodzewicz Z; Hervier B; Cohen-Aubart F; Launay D; Lesot A; Mokhtari K; Canioni D; Galmiche L; Rose C; Schmalzing M; Croockewit S; Kambouchner M; Copin MC; Fraitag S; Sahm F; Brousse N; Amoura Z; Donadieu J; Emile JF
Blood; 2012 Sep; 120(13):2700-3. PubMed ID: 22879539
[TBL] [Abstract][Full Text] [Related]
28. [Erdheim-Chester disease-A histiocytic multisystem disease with unusual renal involvement].
Dasdelen S; Büschek F
Internist (Berl); 2020 Sep; 61(9):969-979. PubMed ID: 32785740
[TBL] [Abstract][Full Text] [Related]
29. Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both
Nordmann TM; Juengling FD; Recher M; Berger CT; Kalbermatten D; Wicki A; Paasinen-Sohns A; Cathomas G; Tzankov A; Daikeler T
Blood; 2017 Feb; 129(7):879-882. PubMed ID: 27940476
[TBL] [Abstract][Full Text] [Related]
30. Successful treatment with cladribine of Erdheim-Chester disease with orbital and central nervous system involvement developing after treatment of Langerhans cell histiocytosis.
Perić P; Antić B; Knezević-Usaj S; Radić-Tasić O; Radovinović-Tasić S; Vasić-Vilić J; Sekulović L; Tarabar O; Tukić L; Jovandić S; Magić Z
Vojnosanit Pregl; 2016 Jan; 73(1):83-7. PubMed ID: 26964390
[TBL] [Abstract][Full Text] [Related]
31. [Langerhans cell histiocytosis and Erdheim-Chester disease, a continuity?].
Parreau S; Haroche J; Pommepuy I; Emile JF; Bourras JC; Archambeaud F
Rev Med Interne; 2017 Jul; 38(7):482-487. PubMed ID: 27889325
[TBL] [Abstract][Full Text] [Related]
32. BRAF inhibitor therapy in HCL.
Dietrich S; Zenz T
Best Pract Res Clin Haematol; 2015 Dec; 28(4):246-52. PubMed ID: 26614903
[TBL] [Abstract][Full Text] [Related]
33. Langerhans cell histiocytosis and Erdheim-Chester disease, both with cutaneous presentations, and papillary thyroid carcinoma all harboring the BRAF(V600E) mutation.
Johnson WT; Patel P; Hernandez A; Grandinetti LM; Huen AC; Marks S; Ho J; Monaco SE; Jaffe R; Picarsic J
J Cutan Pathol; 2016 Mar; 43(3):270-5. PubMed ID: 26454140
[TBL] [Abstract][Full Text] [Related]
34. Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.
Tiacci E; Park JH; De Carolis L; Chung SS; Broccoli A; Scott S; Zaja F; Devlin S; Pulsoni A; Chung YR; Cimminiello M; Kim E; Rossi D; Stone RM; Motta G; Saven A; Varettoni M; Altman JK; Anastasia A; Grever MR; Ambrosetti A; Rai KR; Fraticelli V; Lacouture ME; Carella AM; Levine RL; Leoni P; Rambaldi A; Falzetti F; Ascani S; Capponi M; Martelli MP; Park CY; Pileri SA; Rosen N; Foà R; Berger MF; Zinzani PL; Abdel-Wahab O; Falini B; Tallman MS
N Engl J Med; 2015 Oct; 373(18):1733-47. PubMed ID: 26352686
[TBL] [Abstract][Full Text] [Related]
35. [Erdheim-Chester disease (ECD), an inflammatory myeloid neoplasia].
Haroche J; Papo M; Cohen-Aubart F; Charlotte F; Maksud P; Grenier PA; Cluzel P; Mathian A; Emile JF; Amoura Z
Presse Med; 2017 Jan; 46(1):96-106. PubMed ID: 27234902
[TBL] [Abstract][Full Text] [Related]
36. Erdheim-Chester disease.
Haroche J; Arnaud L; Cohen-Aubart F; Hervier B; Charlotte F; Emile JF; Amoura Z
Rheum Dis Clin North Am; 2013 May; 39(2):299-311. PubMed ID: 23597965
[TBL] [Abstract][Full Text] [Related]
37. Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation.
Hervier B; Haroche J; Arnaud L; Charlotte F; Donadieu J; Néel A; Lifermann F; Villabona C; Graffin B; Hermine O; Rigolet A; Roubille C; Hachulla E; Carmoi T; Bézier M; Meignin V; Conrad M; Marie L; Kostrzewa E; Michot JM; Barete S; Taly V; Cury K; Emile JF; Amoura Z;
Blood; 2014 Aug; 124(7):1119-26. PubMed ID: 24894769
[TBL] [Abstract][Full Text] [Related]
38. Langerhans cell histiocytosis associated with chronic myelomonocytic leukaemia both harbouring the same BRAF V600E mutation: efficacy of vemurafenib.
Konstantinou MP; Lucas P; Uthurriague C; Severino-Freire M; Spenatto N; Gaudin C; Lamant L; Tournier E; Bulai-Livideanu C; Meyer N; Paul C
J Eur Acad Dermatol Venereol; 2021 Feb; 35(2):e120-e121. PubMed ID: 32757402
[No Abstract] [Full Text] [Related]
39. Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease.
McClain K
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):395-399. PubMed ID: 33275721
[TBL] [Abstract][Full Text] [Related]
40. Erdheim-Chester Disease: Comprehensive Review of Molecular Profiling and Therapeutic Advances.
Haroun F; Millado K; Tabbara I
Anticancer Res; 2017 Jun; 37(6):2777-2783. PubMed ID: 28551613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
